NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

纳斯达克 · USD

BioVie Inc. (BIVIW) 股票分析

BioVie Inc.（BIVIW）是在纳斯达克上市的股票，以美元交易。

BIVIW

$0.33

−$0.03 (−8.33%)

2026年9月4日 · 收盘

这是一只衍生品——BioVie Inc.（BIVI）普通股的认股权证。

发行人的基本面数据显示在发行人页面，而非本页。

查看BIVI →

价格走势

悬停查看每日收盘价。虚线表示区间起始价。

BIVIW 关键统计数据

数据截至2026年9月4日
交易
开盘价
$0.32
前收盘价
$0.36
当日波动区间
0.32–0.35
52周波动区间
0.32–0.35
成交量
8.41K
Beta系数股价相对大盘的波动幅度。1.0与大盘同步，高于1.0波动更大，低于1.0更小。
0.74

仅显示公司披露的指标。 数据由Yahoo Finance通过yfinance提供。每日更新。

BIVIW 历年回报率

历年回报率根据每日收盘价计算。 不完整年度以浅色显示并标有星号。

年份回报率
2026 (不完整年度)−3.23%
2025 (不完整年度)+0.00%

数据截至2026年9月4日。

最新新闻

全部8篇文章 ↓

新闻由第三方来源提供。不构成投资建议。

关于BioVie Inc.

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

公司简介以英文显示。

访问官网 →